With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
ApexOnco Front Page
Recent articles
The company’s AN9025 will shortly enter phase 1.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
But the group still hopes to get IGV-001 approved based on overall survival data.
A more comprehensive dataset on JANX007 sends the group’s stock down.
The agency approved eight oncology products over the month.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
